Introduction
The hypothalamic paraventricular nucleus (PVN) is a key brain site involved in the central neural and humoral regulation of body fluid and electrolyte homeostasis (Badoer, 2010) . Located adjacent to the third ventricle, the PVN is composed of a heterogeneous population of neurons including larger magnocellular and smaller parvocellular neurons. From the PVN, magnocellular neurons, which synthesize the neurohypophysial hormones arginine-vasopressin (AVP) and oxytocin, project to the posterior pituitary (Swanson and Sawchenko, 1983) . Following synthesis/storage, AVP (and to a lesser extent, oxytocin) is transported via the hypothalamo-hypophysial tract to the posterior pituitary and secreted into the circulation in response to an increase in plasma osmolality/sodium concentration (predominant mechanism) or a decrease in blood volume/pressure (Swanson and Sawchenko, 1983; Bisset and Chowdery, 1988) .
In regards to regulation of systemic arterial blood pressure, the posterior parvocellular areas of the PVN send long descending projections to premotor sympathetic neurons in the rostral ventrolateral medulla and the nucleus of the solitary tract in the lower brain stem. Projections from the parvocellular neurons of the PVN also synapse directly onto sympathetic preganglionic motoneurons of the interomediolateral cell column of the thoracolumbar spinal cord. Finally, neurosecretory parvocellular neurons of the PVN also project to the external layer of the median eminence where AVP and corticotropinreleasing hormone are secreted into portal blood to coordinate hypothalamic-pituitaryadrenal system activity (Badoer, 2010) .
Circulating blood levels of AVP are largely determined by the electrical activity of the magnocellular neurons in the PVN and superoptic nucleus (SON; Badoer, 2010) . In This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on jpet.aspetjournals.org Downloaded from the PVN (and SON), membrane bound voltage-gated potassium and calcium currents contribute to the phasic activity of AVP magnocellular neurons. Magnocellular activity is also tightly regulated by neurotransmitters and neuromodulators through either postsynaptic mechanisms or by presynaptic modulation, largely of excitatory glutamatergic and inhibitory GABAergic synaptic inputs (Badoer, 2010) .
In addition to GABA, glycine is a major inhibitory neurotransmitter in the brain stem and medulla (Hernandes and Troncone, 2009; Keck and White, 2009) . Following stimulation, strychnine-sensitive glycine receptors play an important inhibitory role in neurotransmission through gating of chloride channels. In addition to their abundance in the spinal cord and brainstem, glycine receptor mRNAs and protein are expressed in forebrain structures including the PVN (Hernandes and Troncone, 2009 ). In the PVN, the parvocellular region receives a dense innervation of glycine-immunoreactive fibers, whereas a smaller quantity of these fibers is expressed in the magnocellular division of this nucleus (Rampon et al., 1996) . These findings suggest that in addition to the wellestablished involvement of glycine as an inhibitory neurotransmitter in the spinal cord and lower brain stem, glycine and its receptor(s) may also have a role in neurotransmission in higher brain structures. In this regard, intracerebroventricular (i.c.v.) administration of glycine to rats has been reported to dose-dependently decrease heart rate and blood pressure and enhance epinephrine-induced reflex bradycardia (Yang and Lin, 1983) . However, it remains unknown whether glycine receptor pathways in the PVN mediate centrally-evoked changes in systemic cardiovascular and/or renal function and if so, whether glycine-induced alterations in neural and/or humoral pathways are involved. This was first performed by determining the cardiovascular and renal excretory responses produced by microinjection of glycine into the PVN of conscious rats. Studies were then performed to examine the role(s) of AVP and intact renal nerves in mediating the cardiovascular and renal responses to PVN glycine. Participation of the renal sympathetic nerves in mediating glycine-induced changes in renal excretory function was examined by directly measuring changes in renal sympathetic nerve activity (RSNA) and repeating the experimental protocol in rats that had undergone chronic bilateral renal denervation. Finally, separate experiments were performed to determine the effects produced by bilateral microinjection of strychnine, a highly selective and potent competitive glycine receptor antagonist (Lee et al., 2009) , into the PVN on cardiovascular and renal excretory function and RSNA. For these studies, strychnine was injected into animals alone or as a pre-treatment before glycine injection.
Strychnine was used to pharmacologically block a potential ongoing tonic influence of glycine in the PVN on a given cardiovascular or renal excretory parameter and to test the receptor selectivity of the action of glycine in this brain nucleus, respectively. This article has not been copyedited and formatted. The final version may differ from this version. 
Surgery.
Aseptic technique was used for all surgeries. Five to seven days prior to investigation, rats were stereotaxically implanted with a chronic stainless steel cannula into the PVN for drug/vehicle injection into this nucleus. On the day of surgery, rats were anesthetized with an i.m. injection of ketamine (50 mg/kg) and xylazine (5 mg/kg) and placed in a stereotaxic apparatus (Kopf, Tujunga, CA). A 2 cm incision was made to expose the scalp and connective tissue was removed to expose the cranial sutures. A 26-gauge stainless steel cannula was directed at the dorsal parvocellular subdivision of the PVN at a 10 angle from the vertical through a burr hole located streotaxically 1.7 mm posterior to the bregma, 1.95 mm laterally to the midline, and 7.8 mm ventral from the skull surface. Inner stylets were inserted into the guide cannulae to prevent their obstruction by clots. The guide cannulae were secured to the skull with three stainless steel machine screws and dental acrylic. All rats received ampicillin (50 mg/kg, s.c.) to prevent post surgery infection. The animals were then placed in individual plastic cages and allowed to recover from the stereotaxic surgery for at least 5-7 days prior to their use in an experimental protocol. For certain experiments, rats (still anesthetized with Brevital) were also implanted with a renal nerve recording electrode for direct measurement of RSNA. For these studies, the left kidney was exposed via a retroperitoneal approach and a renal nerve bundle was dissected carefully and freed from the surrounding tissue under a dissecting microscope (x25). The nerve was placed on a bipolar electrode made of Teflon-coated platinum wire (Cooner Wire, Chatsworth, CA). Spike potentials were amplified (x10,000-50,000) and filtered (low, 30 Hz; high, 3,000 Hz) with a Grass P511 Bandpass Amplifier (Grass Instrument, Quincy, MA). The amplified and filtered signal was channeled to a Grass model 7DA polygraph for visual evaluation, to an audio amplifier-loudspeaker (Grass model AM 8 Audio Monitor) for auditory evaluation, to a rectifying voltage integrator (Grass model 7P10) and continuously recorded on the Grass polygraph and using a data acquisition system (Model MP100; Biopac Systems, Inc., Santa Barbara, CA). The quality of the renal sympathetic nerve signal was assessed by its pulse synchronous rhythmicity. When an optimal renal sympathetic nerve activity signal was observed, the recording electrode was fixed to the renal nerve branch with and covered After surgical preparation rats were placed in a rat holder (a chamber of stainless steel rods connected by Plexiglas ends; the metal rods formed an inverted U shape and a flat base in which the rat would sit) to minimize movement and damage to the renal nerve recording electrode preparation and to permit steady-state urine collection. The animals were then allowed 4-6 hours to fully recover from anesthesia during which time an infusion (50 l/min i.v.) of isotonic saline was started and continued for the duration of the experiment. Prior to the start of the experiment, the arterial catheter was flushed and attached to a pressure transducer (Viggo-Spectramed, model P23XL, Oxnard, CA), and the urinary bladder catheter was lead to a collection vial. Heart rate was derived from the pulse pressure by a tachograph (Grass model 7 P4H), and mean arterial pressure, heart rate, and RSNA were recorded on a Grass model 7 polygraph and a Biopac data acquisition system (Model MP100 and AcqKnowledge 3.7.2 software; Biopac Systems, Inc., Santa Barbara, CA).
Experimental Protocols. Studies were performed to examine changes in the cardiovascular, renal excretory and RSNA responses to unilateral (left) microinjection of glycine into the PVN of conscious rats. After stabilization of cardiovascular, renal excretory, and RSNA parameters, urine was collected during a 20-min control period.
Next, a 33-gauge injection needle connected to 10-µl micro-syringe was inserted into Separate experiments were performed to determine whether changes in circulating levels of AVP play a role in mediating the cardiovascular and/or renal excretory responses produced by the microinjection of glycine into the PVN. For these studies, the experimental protocol described above was repeated in rats (n=5; intact renal nerves) with the exception that following recovery from surgical preparation, AVP was added to the isotonic saline vehicle and continuously infused i.v. throughout the PVN glycine microinjection experiment at a rate of 85 pg/kg/min.
The role of intact renal nerves in mediating the cardiovascular and renal excretory responses produced by the injection of glycine into the PVN was examined by repeating the PVN glycine microinjection protocol in six rats having undergone chronic bilateral renal denervation 10-13 days before experimentation. Renal denervation was performed via bilateral flank incisions and stripping the renal arteries and veins of adventitia, cutting the renal nerve bundles, and coating the vessels with a solution of 10% phenol in absolute ethanol as previously described (DiBona and Sawin, 1983) . This renal denervation procedure prevents the renal vasoconstrictor response to suprarenal lumbar sympathetic nerve stimulation, prevents the antinatriuretic response to environmental stress, reduces renal catecholamine histofluorescence to undetectable levels, and reduces renal tissue noradrenaline concentration to <5% of control for up to 15 days post-denervation (DiBona and Sawin, 1983) . Because our laboratory has previously and repeatedly verified that this renal denervation procedure completely removes the influence of the renal nerves on kidney function (Kapusta and Kenigs, 1999; Krowicki and Kapusta, 2006) , verification of renal denervation was not performed in these studies. Five to eight days after bilateral renal denervation, the same rats were anesthetized with ketamine/xylazine and implanted with a chronic PVN cannula as previously described for microinjection of glycine into this brain site on the day of study.
Additional experiments were performed to evaluate the receptor selectivity of glycine in the PVN and determine whether the native glycine peptide and receptor system in the PVN plays a tonic role in the regulation of cardiovascular and renal function and RSNA. For these studies the selective glycine receptor antagonist, strychnine (Lee et al., 2009 ) was microinjected into the PVN (1.6 nmol) 10 min before vehicle or glycine (50 nmol). Changes in cardiovascular and renal excretory function and RSNA were measured during consecutive 10-min periods before (control) and after drug injection (experimental) for 80 min. Typical responses to L-glutamate in the PVN included increases in heart rate and mean arterial pressure (Krowicki and Kapusta, 2006) . Next, the injection site was marked by the injection of 1% pontamine sky blue dye in the same manner as glycine injection.
The animals were euthanized with an overdose of methohexital sodium and perfused transcardially with saline and 4% paraformaldehyde. The brains were removed, postfixed in the same solution, sectioned at 50 µm and counterstained with neutral red dye for histological confirmation of injection sites. Injections were considered acceptable when the cannula tip was within a distance of 0.5 mm of the PVN boundaries (Krowicki and Kapusta, 2006) . Figure 2 depicts the changes in free water clearance produced by the microinjection of glycine (5 and 50 nmol) or aCSF into the PVN for the same rats in which data are depicted in Fig. 1 . At the lower dose (5 nmol), glycine evoked a delayed, but significant increase in free water clearance 60-min after drug injection (C: -64.212.6 ml/min; 60-min: 19.015.5 ml/min, p<0.05). Similarly, when microinjected into the PVN at a higher dose of 50 nmol, glycine evoked significant increases in free water clearance at the 50-and 60-min time points with a peak at 60-min (C: -77.114.8 ml/min; peak 60-min: 21.113.8 ml/min, p<0.05). Microinjection of aCSF did not significantly alter free water clearance over the course of the study.
The histological identified sites into which glycine (5 and 50 nmol) was microinjected into the PVN of animals for which data are shown in Fig. 1 are illustrated in Fig. 3 . Injections were considered acceptable if the cannula tip was within a distance of 0.5 mm of the PVN boundaries (Krowicki and Kapusta, 2006) . Several sites below and/or lateral to the PVN served as anatomical controls for the glycine injections. No significant responses were elicited from these microinjections (data not shown). In these studies it was observed that the continuous infusion of AVP during the first 40-min prior to the start of the experimental protocol (i.e., stabilization period) produced a slight, but not statistically significant increase in mean arterial pressure, which corresponded with a significant decrease in basal levels for heart rate and RSNA (data not shown). In this and previous studies (Krowicki and Kapusta, 2006) , the AVP-induced decrease in heart rate tended to reach a plateau level in the first 30-min and remained constant thereafter throughout the subsequent AVP infusion protocol (i.e., 80-min post aCSF injection).
As shown in Fig. 4 , the diuretic and natriuretic responses produced by the microinjection of glycine into the PVN of conscious rats (see Fig. 1 ) were completely prevented in rats infused i.v. with AVP. In contrast, i.v. AVP infusion did not alter the ability of PVN glycine to decrease heart rate or RSNA. In AVP infused rats, PVN glycine produced a significant decrease in RSNA (nadir 40 min; 556% of C), which returned to pre-drug control levels 50 min after drug injection. Microinjection of aCSF did not significantly alter any cardiovascular or renal parameter over the course of the study.
Cardiovascular and Renal Effects of Glycine Microinjected into the PVN of
Renal-Denervated Rats. Injection of glycine (50 nmol) into the PVN failed to alter mean arterial pressure or heart rate in chronic bilateral renal denervated rats. In renal 
Cardiovascular and Renal Responses Produced by PVN Glycine in
Conscious Rats Pre-Treated with Strychnine. Figure 5 illustrates the peak changes in cardiovascular and renal responses produced by the unilateral microinjection of aCSF or glycine (50 pmol) into the PVN of conscious rats (n=5/group) pre-treated (10-min) in the same brain site with the selective glycine receptor antagonist, strychnine (1.6 nmol).
Unilateral microinjection of strychnine with subsequent aCSF-treatment evoked a significant increase in RSNA from 10-to 60-min time points with a peak at 20-min (peak: 12312 % of C, p<0.05); Systemic hemodynamic or renal excretory function was not altered. In separate animals, this dose of strychnine completely prevented the marked renal sympathoinhibitory, diuretic, and natriuretic excretion typically produced by PVN glycine. In addition, the bradycardic response typically produced by PVN glycine injection in naive animals ( Fig. 1 ) was converted to a tachycardia in animals that received strychnine pre-treatment (C: 38014 bpm; peak 20-min: 41022 bpm, p<0.05). 
Discussion
The findings of these studies demonstrate that microinjection of glycine into the PVN produces bradycardia, renal sympathoinhibition, and dose-dependent increases in water and sodium excretion from the kidneys of conscious rats. Marked increases in urine output and free-water clearance in response to glycine in the PVN suggest that this neurotransmitter may have an inhibitory influence on magnocellular neuronal activity and the release of AVP into the systemic circulation. This possibility is also suggested by the observation that taurine, which has affinity for glycine receptors, has an inhibitory influence on rat supraoptic nucleus (SON) magnocellular neurons in vitro (Hussy et al, 2000) and in vivo (Huang et al., 2006) . In accordance with this premise, we demonstrated that low-dose i.v. AVP infusion prevented the diuretic (and natriuretic) response to microinjection of glycine into the PVN. Although plasma levels of AVP were not measured in the present study, these results provide strong evidence that inhibition of AVP secretion contributes to the diuretic and natriuretic responses to PVN glycine. As noted above, glycine is not the only ligand for glycine receptors. The endogenous amino acids -alanine and taurine have also been identified in the hypothalamus (Choi et al., 2000) and are able to activate extrasynaptic glycine receptors (Albrecht and Schousboe, 2005) . However, further studies are required to determine whether PVN alanine and/or taurine are able to enhance the renal excretion of water in rats similar to that elicited by PVN glycine.
In addition to diuresis, activation of glycine receptors in the PVN produced a robust natriuresis. This change was accompanied by a significant and long lasting reduction in RSNA. Decreases in RSNA are known to produce reciprocal increases in urinary sodium and water excretion by decreasing the renal sodium and water reabsorption throughout the nephron (DiBona, 2001) . To determine whether the PVN glycine-induced natriuresis was mediated by a pathway involving intact renal nerves, we examined the renal excretory responses to glycine in chronic bilaterally renal denervated rats. In renal denervated rats, glycine did not produce a marked increase in urinary sodium excretion, therefore suggesting that intact renal nerves appear to be required to mediate the natriuresis to PVN glycine. However, it is important to note that in these renal denervated animals the natriuresis to PVN glycine may have, at least in part, been masked by a prior reduction in urine output and urinary sodium excretion (marked) that occurred immediately following PVN microinjection of glycine. The possibility that the renal nerves may instead only have a contributory role in mediating the renal excretory responses to PVN glycine is supported by the observation that diuretic and natriuretic, but not renal sympathoinhibitory responses to PVN glycine were completely abolished in rats infused with low dose of AVP.
Our findings demonstrate that the diuretic and natriuretic responses to PVN glycine were abolished by PVN pretreatment of animals with strychnine, thus demonstrating the role of glycine receptors in these renal excretory responses.
However, instead of simply blocking the inhibitory responses on heart rate and RSNA, we observed that glycine produced tachycardia and renal sympathoexcitation in strychnine-treated animals. This observation suggests that in this setting (i.e., blockade of glycine receptors), the cardiovascular and renal sympathetic effects of glycine in the PVN may be mediated through strychnine-insensitive glycine receptors, which are allosteric binding sites in the NMDA receptor-channel complex (Furuya and Ogura, This article has not been copyedited and formatted. The final version may differ from this version.
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As suggested above, the findings of this study suggest that endogenous activation of glycine pathways in the PVN may contribute to the renal handling of water and osmoregulation. In addition, it may be speculated that PVN glycine may have an important physiological role in regulating central sympathetic outflow to the heart. In support of this premise, endogenous glycine levels have been shown to be increased in the micordialysate from the PVN during a time in which arterial blood pressure is increased via i.v. phenylephrine (Yin et al., 2009) . In these studies, microinjection of strychnine into the PVN enhanced the pressor response to i.v. phenylephrine and attenuated the baroreflex-induced bradycardia. Further, and in agreement with the findings of the present study, perfusion of glycine into the PVN enhanced the baroreflexinduced bradycardic, but not pressor response to i.v. phenylephrine (Yin et al., 2009 ).
We also provide direct evidence that the endogenous glycinergic system in the rat PVN is tonically active. The evidence is based on our observations that bilateral microinjection of the glycine receptor antagonist, strychnine, into the PVN of conscious rats produced tachycardia and a marked increase in RSNA. These are responses which are opposite in direction to the effects of PVN glycine in naive animals. In contrast, however, it appears that endogenous PVN glycine pathways are not tonically involved in the control of AVP secretion. This is suggested by the observation that bilateral PVN microinjection of strychnine did not alter urine flow rate or urinary sodium excretion.
Considering that bilateral strychnine did increase RSNA, it could be predicted that PVN glycine receptor blockade may decrease urinary sodium excretion. While this was not Together, the findings of these investigations demonstrate that the activation of glycine receptor pathways in the PVN of conscious rats evokes significant changes in heart rate (bradycardia) and the renal excretion of water and sodium. The diuretic and natriuretic responses to PVN glycine occur through pathways that concurrently involve neural (renal sympathoinhibitory) and humoral (AVP inhibitory; predominant) influences on the renal excretion of water and sodium. Additionally, this study provides evidence for a physiological role for the endogenous glycine system in the PVN in the tonic inhibitory control of central sympathetic outflow to the heart and kidneys. On the basis of these findings, it may be speculated that the endogenous glycine system in the PVN may participate in the inhibitory control of AVP secretion and RSNA under stressful/pathological conditions in which it is necessary to promote the renal excretion of water and sodium to maintain body fluid/electrolyte homeostasis. In addition, endogenous glycine may act in the PVN via strychnine-sensitive glycine receptors to provide an inhibitory influence on central sympathetic outflow to the heart, which may potentially facilitate the cardiac baroreflex. Further studies are required to fully understand the importance of this novel system and determine how glycine interacts with other neurotransmitters in the PVN in the control of cardiovascular and renal function. 
